{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:cardiac-glycosides-digoxin",
  "owner": "cardio",
  "kind": "drug",
  "slug": "cardiac-glycosides-digoxin",
  "name": "Cardiac glycosides (digoxin)",
  "aliases": [
    "Cardiac glycosides",
    "Cardiac glycoside",
    "Digitalis glycosides",
    "Cardiotonic steroids"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Cardiac glycosides, also called digitalis glycosides, are a group of medicines that act on the heart muscle. MeSH says they increase the force of heart contraction but are very toxic at larger doses. Digoxin (Lanoxin) is the one medicine of this group with a page in this atlas, and that page is filed under this class. This is the class page.",
  "summary_technical": "Class page. MeSH descriptor D002301 (Cardiac Glycosides) is an exact match; its entry terms include Cardiac Glycoside and Cardiotonic Steroid (read 2026-11-18, hash only). The scope note says plants they come from have long been used in congestive heart failure, that the compounds increase the force of cardiac contraction, and that the mechanism usually involves inhibition of the sodium-potassium ATPase. The Lanoxin label read (Advanz Pharma (US) Corp., NDA020405, effective 2024-12-05) calls Lanoxin a cardiac glycoside and one of the cardiac (or digitalis) glycosides, and lists, for adults, mild to moderate heart failure and control of resting ventricular rate in chronic atrial fibrillation among its indications. RxClass lists Cardiac Glycoside as the established pharmacologic class of digoxin on US drug labels; digoxin is filed under this page on that evidence. MeSH also places cardiac glycosides among the agents that strengthen the heart; a separate class page covers that wider group. No trial result and no dose is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": "2027-05-18",
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D002301",
      "normalized_value": "D002301",
      "match": "exact",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "heart-failure",
        "arrhythmias"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "MeSH says the mechanism of these compounds usually involves inhibition of the sodium-potassium ATPase enzyme."
  },
  "content_digest": "032782024bf23428ff8ebe55b0339069cd58c510b57f2c6713b5ccb34233b08b",
  "review": {
    "content_digest": "032782024bf23428ff8ebe55b0339069cd58c510b57f2c6713b5ccb34233b08b",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MeSH: plants these compounds come from have long been used in heart failure",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:heart-failure",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "A US digoxin label lists control of resting ventricular rate in adults with chronic atrial fibrillation",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:atrial-fibrillation",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MeSH names cardiac glycosides among cardiotonic agents",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:inotropes-and-vasopressors",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:digoxin",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-3407-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/cardiac-glycosides-digoxin/",
  "context_path": "api/v1/context/cardio--cardiac-glycosides-digoxin.md"
}
